Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Liso-cel for aggressive B-cell NHL

Raúl Córdoba • 22 Jun 2020
EHA 2020
Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel
TRANSCEND-PILOT-017006

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, discusses results from the Phase II TRANSCEND-PILOT-017006 study (NCT03483103) evaluating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in relapsed/refractory large B-cell non-Hodgkin lymphoma (NHL) patients. Specifically discussed is the potential impact of this CAR T-cell therapy on elderly, unfit patients with comorbidities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies 1:30
The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba • 15 Jun 2024
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2 1:11
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raúl Córdoba • 15 Jun 2024
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies 1:27
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raúl Córdoba • 15 Jun 2024
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL 2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals